Literature DB >> 33260352

Role of Surgical Intervention in Unresectable Non-Small Cell Lung Cancer.

Shigeki Suzuki1, Taichiro Goto2.   

Abstract

With the development of systemic treatments with high response rates, including tyrosine kinase inhibitors and immune checkpoint inhibitors, some patients with unresectable lung cancer now have a chance to undergo radical resection after primary treatment. Although there is no general consensus regarding the definition of "unresectable" in lung cancer, the term "resectable" refers to technically resectable and indicates that resection can provide a favorable prognosis to some extent. Unresectable lung cancer is typically represented by stage III and IV disease. Stage III lung cancer is a heterogeneous disease, and in some patients with technically resectable non-small cell lung cancer (NSCLC), multimodality treatments, including induction chemoradiotherapy followed by surgery, are the treatments of choice. The representative surgical intervention for unresectable stage III/IV NSCLC is salvage surgery, which refers to surgical treatment for local residual/recurrent lesions after definitive non-surgical treatment. Surgical intervention is also used for an oligometastatic stage IV NSCLC. In this review, we highlight the role of surgical intervention in patients with unresectable NSCLC, for whom an initial complete resection is technically difficult. We further describe the history of and new findings on salvage surgery for unresectable NSCLC and surgery for oligometastatic NSCLC.

Entities:  

Keywords:  immunotherapy; non-small cell lung cancer; oligometastasis; salvage surgery; targeted therapy; unresectable

Year:  2020        PMID: 33260352     DOI: 10.3390/jcm9123881

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  6 in total

1.  Efficacy and safety of thoracoscopic resection for early-stage non-small cell lung cancer.

Authors:  Peng Cao; Jiaqi Yue; Shan Hu; Kangle Kong; Peng Han; Ziheng Yang; Yu Deng; Fan Li; Bo Zhao
Journal:  Am J Transl Res       Date:  2022-06-15       Impact factor: 3.940

Review 2.  The role of the surgeon in the management of oligometastatic non-small cell lung cancer: a literature review.

Authors:  Lawek Berzenji; Sophie Debaenst; Jeroen M H Hendriks; Suresh Krishan Yogeswaran; Patrick Lauwers; Paul E Van Schil
Journal:  Transl Lung Cancer Res       Date:  2021-07

3.  Deep Q-networks with web-based survey data for simulating lung cancer intervention prediction and assessment in the elderly: a quantitative study.

Authors:  Songjing Chen; Sizhu Wu
Journal:  BMC Med Inform Decis Mak       Date:  2022-01-04       Impact factor: 2.796

Review 4.  [Molecule pathology in the treatment of lung cancer-Interdisciplinary view of the importance in thoracic surgery].

Authors:  Sebastian Krämer; Hubert Wirtz
Journal:  Chirurg       Date:  2021-12-14       Impact factor: 0.920

Review 5.  Patient Selection for Local Aggressive Treatment in Oligometastatic Non-Small Cell Lung Cancer.

Authors:  Raphael S Werner; Isabelle Opitz
Journal:  Cancers (Basel)       Date:  2021-12-19       Impact factor: 6.639

6.  12 × 6 Gy stereotactic radiotherapy for lung tumors. Is there a difference in response between lung metastases and primary bronchial carcinoma?

Authors:  Dorota Lubgan; Sabine Semrau; Ulrike Lambrecht; Udo S Gaipl; Rainer Fietkau
Journal:  Strahlenther Onkol       Date:  2021-07-13       Impact factor: 3.621

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.